Cullinan Therapeutics, Inc. (CGEM)
CGEM moved a median of +0.29% 30 minutes after news, and -0.16% by the close. How CGEM actually reacts to news — the realized, point-in-time move the market made, measured across 264 labeled events over the last three years with zero look-ahead.
CGEM’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.18% | 55% | 262 |
| 30-min | +0.29% | 55% | 264 |
| 60-min | -0.33% | 41% | 264 |
| to close | -0.16% | 49% | 264 |
| Middle 50% of CGEM reactions | -1.99% to +1.62% |
|---|---|
| Median reaction (30-min) | +0.29% |
| Measured reactions | 264 |
Half of all Cullinan Therapeutics, Inc. news events land between -1.99% and +1.62% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How CGEM reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 27 | -1.01% | 37% | -0.16% |
| Rating reiterations | 60 | +0.22% | 52% | -0.61% |
| Price-target raises | 10 | -1.40% | 20% | -2.47% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how CGEM ranks against every other measured name →
That’s how CGEM usually reacts — get an email when it moves on news →Email me when CGEM moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CGEM's baseline. Nothing else.
Recent CGEM events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Cullinan Therapeutics Announces First Patient Dosed in Planned Registrational Phase 2 Study of CLN-049 in Relapsed/Refractory Acute Myeloid Leukemia | Press release | GlobeNewswire | -2.37% | -0.90% | |
| Form 8-K Cullinan Therapeutics, For: Oct 01 | SEC filing · Form 8-K | SEC EDGAR | +0.47% | +5.08% | |
| New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program | Press release | GlobeNewswire | +0.47% | +5.08% | |
| Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio | Press release | GlobeNewswire | +0.26% | -7.32% | |
| Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum | Press release | GlobeNewswire | -0.10% | +1.28% | |
| Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer | Press release | GlobeNewswire | +3.80% | +4.72% | |
| Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer | Press release | Business Wire | +3.80% | +4.72% | |
| Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer | Press release | GlobeNewswire | +0.69% | +0.14% | |
| Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer | Press release | Business Wire | +0.42% | +4.60% | |
| Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer | Press release | Business Wire | -4.33% | -4.75% | |
| Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -1.64% | +1.58% | |
| Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML | Press release | GlobeNewswire | -1.45% | -0.85% | |
| Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases | Press release | GlobeNewswire | +3.04% | -8.29% | |
| Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress | Press release | GlobeNewswire | -3.39% | -3.21% | |
| Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager | Press release | GlobeNewswire | -0.60% | +9.26% | |
| Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia | Press release | GlobeNewswire | -6.07% | -4.35% | |
| Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress | Press release | GlobeNewswire | -6.07% | -4.35% | |
| Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | -1.91% | -1.27% | |
| U.S. Food and Drug Administration Accepts New Drug Application for Zipalertinib for the Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | Press release | Business Wire | +0.90% | -4.40% | |
| Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -2.67% | -5.27% | |
| Form 10-K Cullinan Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -2.67% | -5.27% | |
| Form 8-K Cullinan Therapeutics, For: Mar 10 | SEC filing · Form 8-K | SEC EDGAR | -2.67% | -5.27% | |
| Form S-8 Cullinan Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | -2.67% | -5.27% | |
| Cullinan Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -1.52% | -1.38% | |
| Cullinan Therapeutics to Participate in Fireside Chat at the Citi 2026 Virtual Oncology Leadership Summit | Press release | GlobeNewswire | +3.03% | +1.97% | |
| Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 | Press release | GlobeNewswire | +1.41% | -2.07% | |
| Cullinan Therapeutics Provides Corporate Update and Highlights Anticipated 2026 Milestones | Press release | GlobeNewswire | +3.64% | +4.01% | |
| Form 8-K Cullinan Therapeutics, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +3.64% | +4.01% | |
| Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting | Press release | GlobeNewswire | +6.56% | +14.08% | |
| Form 8-K Cullinan Therapeutics, For: Dec 08 | SEC filing · Form 8-K | SEC EDGAR | -1.88% | +6.33% | |
| Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia | Press release | GlobeNewswire | -3.25% | -5.45% | |
| Form 8-K Cullinan Therapeutics, For: Nov 18 | SEC filing · Form 8-K | SEC EDGAR | +3.07% | +34.69% | |
| Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR E | Press release | PR Newswire | +0.81% | +1.04% | |
| Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting | Press release | GlobeNewswire | +2.28% | -0.40% | |
| Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results | Press release | GlobeNewswire | -1.76% | -0.41% | |
| Form 10-Q Cullinan Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.76% | -0.41% | |
| Form 8-K Cullinan Therapeutics, For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | -1.76% | -0.41% | |
| Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting | Press release | GlobeNewswire | +1.28% | -8.87% | |
| Form 8-K Cullinan Therapeutics, For: Nov 03 | SEC filing · Form 8-K | SEC EDGAR | +1.28% | -8.87% | |
| Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025 | Press release | GlobeNewswire | +3.63% | +0.88% | |
| Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib in Patients with NSCLC with EGFR mutations and Active Brain Metastases at the ESMO Congress 2025 | Press release | PR Newswire | -1.82% | +1.95% | |
| Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum | Press release | GlobeNewswire | -1.83% | -0.61% | |
| Taiho Oncology and Cullinan Therapeutics Present Data on Zipalertinib at the IASLC 2025 World Conference on Lung Cancer | Press release | PR Newswire | -1.16% | -0.87% | |
| Form 8-K Cullinan Therapeutics, For: Sep 04 | SEC filing · Form 8-K | SEC EDGAR | -2.08% | -10.26% | |
| Cullinan Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +0.97% | +5.54% | |
| Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results | Press release | GlobeNewswire | +1.45% | -7.62% | |
| Form 10-Q Cullinan Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.45% | -7.62% | |
| Form 8-K Cullinan Therapeutics, For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | +1.45% | -7.62% | |
| Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer | Press release | PR Newswire | +1.60% | +7.85% | |
| Form 8-K Cullinan Therapeutics, For: Jun 12 | SEC filing · Form 8-K | SEC EDGAR | +1.02% | -2.16% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CGEM section they belong to.
Where else CGEM is measured.
CGEM earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cullinan Therapeutics, Inc.'s median reaction calculated?
Every labeled CGEM news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 264 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 55% of CGEM's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CGEM's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.